Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Small Cap
  • Trading Ideas

FDA Requests For Additional Monitoring For Travere Therapeutics’ Sparsentan In Rare Kidney Disease

By Vandana Singh
October 14, 10:02 AM
Following late-cycle review interactions with the FDA, Travere Therapeutics Inc (NASDAQ:TVTX) expects the previously assigned Prescription Drug User Fee Act…

TVTX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • M&A
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Imara Agrees To Merge With Precision Oncology Player, Shares Surge

By Vandana Singh
October 14, 9:15 AM
Enliven Therapeutics Inc and Imara Inc (NASDAQ:IMRA) agreed to merge in an all-stock transaction.  The combined company will focus on advancing Enliven’s…

IMRA

Read More
4 minute read
  • Biotech
  • FDA
  • General
  • News

BMF-219 Enters the Clinic For KRAS Solid Tumor; Biomea Fusion Announces FDA Clearance Of Investigational New Drug Application For Covalent Menin Inhibitor BMF-219 In KRAS Solid Tumors

By Benzinga Newsdesk
October 14, 9:02 AM
Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.   Biomea Fusion will now initiate a Phase I/Ib clinical trial

BMEA

Read More
1 minute read
  • FDA
  • News

Moleculin Provides Update On Second Multiple Ascending Dose (MAD) Cohort In Phase 1a Clinical Trial Of WP1122 In UK; Shares Move Lower

By Benzinga Newsdesk
October 14, 8:42 AM
 Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors

MBRX

Read More
3 minute read
  • Biotech
  • FDA
  • General
  • News

T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations

By Benzinga Newsdesk
October 14, 8:39 AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the publication of three new, peer-reviewed studies that demonstrate

TTOO

Read More
5 minute read
  • Biotech
  • FDA
  • General
  • News

Mirum Pharmaceuticals Announces CHMP Opinion For LIVMARL Oral Solution For Cholestatic Pruritus In Patients With Alagille Syndrome Two Months Of Age And Older

By Benzinga Newsdesk
October 14, 8:07 AM
- CHMP opinion based on pivotal ICONIC study with more than five years of data demonstrating durable and clinically meaningful improvements in cholestatic pruritus and serum bile acids for patients with Alagille syndrome

MIRM

Read More
1 minute read
  • FDA
  • News

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i

By Benzinga Newsdesk
October 14, 7:33 AM
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samples   Increase in the ratio of glycosylated αDG to total

BBIO

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Regeneron Pharmaceuticals Announces Libtayo Receives Positive CHMP Opinion Recommending Approval To Treat Advanced Cervical Cancer

By Benzinga Newsdesk
October 14, 7:05 AM
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for

REGN

Read More
1 minute read
  • FDA
  • News

BeiGene Receives Positive CHMP Opinion For BRUKINSA (zanubrutinib) For Treatment Of Adults With CLL

By Benzinga Newsdesk
October 14, 6:30 AM
BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)))), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today

BGNE

Read More
1 minute read
  • FDA
  • News

Reata Pharmaceuticals Announces FDA Does Not Plan To Hold Advisory Committee Meeting To Discuss The NDA For Omaveloxolone For Friedreich’s Ataxia

By Michael Horton
October 13, 4:38 PM
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, announced that the U.S. Food

RETA

Posts pagination

Previous 1 … 659 660 661 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service